Chugai Venture Fund

Chugai Venture Fund (CVF) is a corporate venture capital fund and subsidiary of Chugai Pharmaceutical Co., Ltd., founded in 2023 and headquartered in Boston, Massachusetts. CVF invests in early-stage, preclinical life science companies whose science aligns with Chugai Pharmaceuticals' R&D priorities. Target areas include new target identification, platform technologies applicable across multiple therapeutic areas, and therapeutics in oncology, immunology, CNS, ophthalmology, metabolic diseases, and rare diseases. The fund also backs AI-driven drug discovery platforms. Typical check size is in the mid-single-digit millions of dollars, with reserves for follow-on investments. CVF focuses its investments in the United States, Western Europe, and Japan. Portfolio companies have included Ten63 Therapeutics, Dualitas Therapeutics, Leal Therapeutics, and Repertoire Immune Medicines. No public application portal is listed; founders are directed to contact the team via the website.